BIOMAT Database Logo BIOMAT Database Logo

Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer. 2005

Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Division of Urology, Oregon Health & Science University, Portland, Oregon 97239, USA.

A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon.

UI MeSH Term Description Entries
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein

Related Publications

Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients.
August 2017, BMC urology,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
May 2018, BMC cancer,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Gonadotropin-releasing hormone antagonist in the management of prostate cancer.
January 2004, Reviews in urology,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
March 1993, The Journal of urology,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
July 2006, International journal of urology : official journal of the Japanese Urological Association,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.
March 2016, Laboratory investigation; a journal of technical methods and pathology,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer.
January 2003, Prostate cancer and prostatic diseases,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Androgen selectively stimulates follicle-stimulating hormone-beta mRNA levels after gonadotropin-releasing hormone antagonist administration.
March 1990, Biology of reproduction,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
January 2024, The Journal of urology,
Matthew Wagner, and Mark Garzotto, and Dianne Lemmon, and Kristine M Eilers, and Tomasz M Beer
Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
January 1998, Urologia internationalis,
Copied contents to your clipboard!